Kvorning Ternov, Klara <br/><br/>
Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.  [electronic resource] 

 -  BMJ open  09 2019 
 - e030218 p.  digital 
<br/><br/> Publication Type: Clinical Trial Protocol; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2044-6055 
<br/><br/><label>Standard No.: </label>10.1136/bmjopen-2019-030218  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Androgen Antagonists--adverse effects<br/>Androstenes--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Benzamides<br/>Blood Glucose--metabolism<br/>Clinical Trials, Phase III as Topic<br/>Denmark<br/>Fatigue--chemically induced<br/>Humans<br/>Male<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Staging<br/>Nitriles<br/>Phenylthiohydantoin--adverse effects<br/>Prednisolone--adverse effects<br/>Prostatic Neoplasms, Castration-Resistant--drug therapy<br/>Quality of Life<br/>Randomized Controlled Trials as Topic<br/>Risk Assessment<br/>Survival Analysis<br/>Treatment Outcome